SC
TEVA icon

Scotia Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Scotia Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$378K Sell
12,564
-3,598
-22% -$116K ﹤0.01% 722
2025
Q4 		$504K Buy
16,162
+3,317
+26% +$81.7K ﹤0.01% 654
2025
Q3 		$260K Hold
12,845
– – ﹤0.01% 790
2025
Q2 		$215K Hold
12,845
– – ﹤0.01% 783
2025
Q1 		$197K Sell
12,845
-196
-2% -$3.5K ﹤0.01% 785
2024
Q4 		$288K Buy
13,041
+125
+1% +$2.27K ﹤0.01% 713
2024
Q3 		$233K Buy
12,916
+45
+0.3% +$788 ﹤0.01% 746
2024
Q2 		$209K Buy
12,871
+578
+5% +$8.9K ﹤0.01% 755
2024
Q1 		$173K Buy
12,293
+26
+0.2% +$328 ﹤0.01% 774
2023
Q4 		$128K Sell
12,267
-30
-0.2% -$280 ﹤0.01% 758
2023
Q3 		$126K Hold
12,297
– – ﹤0.01% 731
2023
Q2 		$92.6K Hold
12,297
– – ﹤0.01% 752
2023
Q1 		$109K Hold
12,297
– – ﹤0.01% 741
2022
Q4 		$112K Sell
12,297
-325
-3% -$2.84K ﹤0.01% 739
2022
Q3 		$102K Buy
12,622
+25
+0.2% +$221 ﹤0.01% 732
2022
Q2 		$95K Sell
12,597
-1,034
-8% -$9.01K ﹤0.01% 760
2022
Q1 		$128K Buy
13,631
+2,234
+20% +$18.6K ﹤0.01% 826
2021
Q4 		$91K Buy
11,397
+161
+1% +$1.45K ﹤0.01% 843
2021
Q3 		$109K Buy
11,236
+260
+2% +$2.44K ﹤0.01% 829
2021
Q2 		$109K Sell
10,976
-470
-4% -$4.97K ﹤0.01% 803
2021
Q1 		$132K Sell
11,446
-989
-8% -$11.3K ﹤0.01% 761
2020
Q4 		$120K Sell
12,435
-107
-0.9% -$1.02K ﹤0.01% 723
2020
Q3 		$113K Sell
12,542
-4,033
-24% -$42.7K ﹤0.01% 672
2020
Q2 		$209K Buy
16,575
+325
+2% +$3.68K ﹤0.01% 576
2020
Q1 		$146K Buy
16,250
+1,588
+11% +$16.3K ﹤0.01% 586
2019
Q4 		$144K Sell
14,662
-2,469
-14% -$22K ﹤0.01% 704
2019
Q3 		$118K Sell
17,131
-387
-2% -$2.96K ﹤0.01% 691
2019
Q2 		$162K Sell
17,518
-1,579
-8% -$19K ﹤0.01% 682
2019
Q1 		$299K Sell
19,097
-29,227
-60% -$515K ﹤0.01% 582
2018
Q4 		$745K Sell
48,324
-9,150
-16% -$188K 0.01% 400
2018
Q3 		$1.24M Sell
57,474
-99,411
-63% -$2.31M 0.02% 365
2018
Q2 		$2.64M Buy
156,885
+625
+0.4% +$12.7K 0.04% 251
2018
Q1 		$2.67M Buy
156,260
+104,520
+202% +$2.04M 0.04% 253
2017
Q4 		$981K Sell
51,740
-110,408
-68% -$1.66M 0.01% 415
2017
Q3 		$2.85M Sell
162,148
-140,877
-46% -$3.17M 0.04% 231
2017
Q2 		$10.1M Buy
303,025
+46,402
+18% +$1.44M 0.17% 94
2017
Q1 		$8.24M Buy
256,623
+151,350
+144% +$5.17M 0.14% 105
2016
Q4 		$3.82M Buy
105,273
+10,120
+11% +$404K 0.06% 203
2016
Q3 		$4.38M Buy
95,153
+8,953
+10% +$467K 0.08% 171
2016
Q2 		$4.33M Buy
86,200
+3,247
+4% +$173K 0.09% 153
2016
Q1 		$4.44M Buy
82,953
+20
+0% +$1.17K 0.1% 129
2015
Q4 		$5.44M Hold
82,933
– – 0.12% 137
2015
Q3 		$4.68M Buy
82,933
+1,296
+2% +$84K 0.11% 147
2015
Q2 		$4.84M Sell
81,637
-3,030
-4% -$187K 0.1% 152
2015
Q1 		$5.28M Sell
84,667
-145
-0.2% -$8.43K 0.14% 119
2014
Q4 		$4.88M Buy
84,812
+1,700
+2% +$94.7K 0.13% 113
2014
Q3 		$4.47M Sell
83,112
-8,635
-9% -$457K 0.1% 128
2014
Q2 		$4.81M Buy
91,747
+8,145
+10% +$416K 0.1% 121
2014
Q1 		$4.42M Buy
83,602
+8,432
+11% +$390K 0.1% 126
2013
Q4 		$3.01M Sell
75,170
-26,427
-26% -$1.04M 0.07% 160
2013
Q3 		$3.84M Buy
101,597
+2,359
+2% +$92K 0.1% 125
2013
Q2 		$3.89M Buy
+99,238
New +$3.86M 0.15% 101

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Scotia Capital's TEVA Position: Q1 2026 in Review

Scotia Capital reduced its Teva Pharmaceuticals (TEVA) stake by 22% in Q1 2026, selling an estimated $116K and leaving 12,564 shares worth $378K. The position accounts for ﹤0.01% of the portfolio, ranked #722.

Scotia Capital first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.1M in Q2 2017. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Scotia Capital held 12,564 shares of Teva Pharmaceuticals worth $378K as of Q1 2026.
  • Scotia Capital sold 3,598 Teva Pharmaceuticals shares in Q1 2026, an estimated $116K.
  • Teva Pharmaceuticals made up ﹤0.01% of Scotia Capital's portfolio in Q1 2026, its #722 holding.
  • Scotia Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Scotia Capital's Teva Pharmaceuticals position peaked at $10.1M in Q2 2017.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.